Value Frameworks in Oncology: What are they and how will they be used?

Dr. Israel was able to share her experience in value framework in oncology with the bladder cancer community. The idea behind value framework from ASCO is focus to support informed, shared decision making between doctor and patient. Its goal is to develop and employ a tool that can customize information for each patient, and to remind the physician that the primary responsibility is the patient. 

Patient Focused Pathology Reports


Dr. Mossonen gave a very interesting discussion regarding the interpretability of the pathology report to the true owner of the report… the patient. His research focuses around presenting information to the patient in a method in which the patient will understand, and be able to retain.

Quality of life considerations for patients with Muscle Invasive Bladder Cancer

Angela Smith gave an excellent review on quality of life in patients with bladder cancer. She recognizes that the majority of QOL literature retrospective, and often results are mixed.

Bladder cancer preservation: Biomarkers of Response

Dr. Kiltie presented an update on biomarkers in predicting response to trimodality therapy. MRE 11 may is a possible predictive biomarker is it demonstrated a predictive of response to cisplatin in chemo RT. A summary of the markers assessed, she summarized that for chemoradiation: a high CRP is associated with a worse cancer specific survival, eGFR is associated with improved disease specific survival, Her 2 is associated with a reduced complete response after chemotherapy, and Ki67 is associated with a worse overall survival.

Keynote Address: Integrating Palliative and Oncology Care in Patients with Advanced Cancer

This years Bladder Cancer Advocacy Network meeting started off strong with an important discussion on Integrating Palliative and Oncology care in patients with Advanced Bladder Cancer by Dr. Jennifer Temel. Dr. Temel is a pulmonary medical oncologist from Massachusetts General Hospital who specializes in palliative treatment and is known for her work in integrating an early palliative care approach in the  treatment of advanced lung cancer.

Intervening Financial Toxicity: What we can do today?

Financial burden of health care treatment affects patients’ financial well-being, quality of life and access to care. Dr. Zafar’s message included preventing financial toxicity, assessing financial toxicity, and reducing financial toxicity. To prevent we should focus on high value care.

Financial Toxicity: Measuring its height by the Shade it Casts

Jonas de Souza was one of four speakers in the financial toxicity forum at this years’ Bladder Cancer Advocacy Network meeting. He gave an excellent evidence-based presentation regarding Financial Toxicity and it’s Burden.  
Page 1 of 2

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.